There is a plethora of analytics reports, including ones by Deloitte, DKV Global, and Ernst and Young, all ...
(Last updated: 23.08.2018) Online marketplaces are websites with a “many-to-many” business logic. They can host multiple suppliers trading ...
/Last update -- 24 Dec 2019/ A background context -- opportunities and challenges Current widespread interest towards artificial intelligence ...
The application of artificial intelligence (AI) in the pharmaceutical industry has become a long-term strategic priority for most ...
In The Spotlight
Get Ready For “Super-platforms” In Healthcare and Pharmaceutical Research
The congress covers the latest in Multi-Omic Single Cell Analysis - discuss and debate the critical challenges and opportunities in Genomic, Transcriptomics and Proteomics. Updates and highlights in Spatial Transcriptomics, Genomics and Digital Spatial Profiling as well as implications on sample and data analysis. Latest advancements in single cell analysis in drug discovery and development including key therapeutic applications in oncology, neurology and immuno-oncology, and the latest diagnostics development. Overcoming Challenges in library preparation, bioinformatics and multi-omic data integration.
SMi group presents the launch of the inaugural Disruptive Technologies in Pharma conference taking place in London on 20th-21st January, 2020.
As new technologies are being incorporated into pharma it is crucial, we reflect on trends in cutting-edge innovation and explore new tech-enabled opportunities to cut costs and save time.
This Congress has a reputation for advancing pathology practice by exploring the implementation of digital pathology and artificial intelligence to advance patient care.
40+ presentations over two days offer the opportunity to discover more about the latest advances and applications of digital pathology. Learn how artificial intelligence and machine learning is being applied to primary diagnosis and clinical research and how the image-based information environment is transforming the laboratory.
This Congress will explore the novel technologies and manufacturing strategies accelerating the efficient production of next-generation biologics.
With 30+ presentations over two days, this meeting focuses on key challenges within the field, evaluating innovative solutions such as continuous bioprocessing, SUTs, data integrity, PAT and the implementation of industry 4.0, all of which aim to increase the efficiency and yield of therapeutic production whilst maintaining high-quality standards. Once again, this meeting will also feature a track dedicated to the manufacturing of cell and gene therapies, exploring both the regulatory and manufacturing challenges of these complex products.
This Congress aim to advance pathology practice by exploring the implementation and use of digital pathology and artificial intelligence to advance patient care.
40+ presentations over two days will offer the opportunity to discover more about the latest advances and applications of digital pathology. Learn how artificial intelligence and machine learning is being applied to primary diagnosis and clinical research and how the image-based information environment is transforming the laboratory.
Featuring a world-class panel of speakers and 20+ presentations, the congress will cover the latest in the future of NGS and long lead sequencing, and benefit from critical discussions and thought-provoking presentations on Long read sequencing For Human Genomes And De Novo Studies, Data analysis in denovo assembly and structural variants, Bioinformatics and mapping tools. Plus, Deliver Genomic Based Medicine - Applications of long and short read sequencing in the Clinic.
Discover the AI methods & tools set to revolutionize healthcare, pharmaceuticals, medicine & diagnostics, as well as industrial applications and key insights. Hear from industry-leading experts on the latest technological advancements and business use cases for 2020!
With major developments in the peptide field and with more and more peptide and oligonucleotide therapeutics entering clinical trials, the real promise of peptides and oligonucleotides is starting to be realised. Part of our Biologics Series, this event will take you through the key stages of peptide development from peptide discovery through to formulation and delivery, manufacturing and synthesis, as well as oligonucleotide synthesis, chemistry, formulation, as well as therapeutics and manufacturing.
The congress will showcase the latest technologies, drugs and in vivo therapeutic solutions that are being produced by pioneers in the genome editing field. The congress will feature over 30 presentations in a comprehensive conference programme designed to provide an increased knowledge of current trends influencing gene editing research. Key speakers include Directors from Novartis, Pfizer, Harvard, MIT and more.
The Intelligent Health AI global summit series, in partnership with NHSX, will bring the AI and health community to the ExCeL London next February to advance discussions on how to apply AI and drive technological collaboration in healthcare.
The Future is Now
The UK’s most forward thinking event, dedicated to exhibiting technology which is really just beginning to be introduced across hospital services, this truly is a pioneering event that will shape the future of healthcare.
Co-located with the Medical Imaging Convention and the Oncology Convention, join over 4000 medical professionals at the UK’s leading medical event for AI & Machine Learning.
The digital transformation of biopharmaceutical manufacturing is continuing at a rapid pace as companies attempt to mine the sources of data available. Innovations include predictive analytics, big data analytics, and creating the digital plant. Digital transformation offers a mechanism to revise its business model, to improve production processes, to design new drugs faster by using artificial intelligence to screen compounds and to increase responsiveness to customers. Furthermore, the volume of data processed by pharmaceutical firms shows no sign of slowing down. This means pharmaceutical companies must act quickly in terms of building core internal digital capabilities and moving beyond their traditional IT functions to all areas of the business.
There is a plethora of analytics reports, including ones by Deloitte, DKV Global, and Ernst and Young, all pointing out to a declining business performance of the pharmaceutical industry. They all convey a similar bottomline message: the decline is not due to a lack of innovation (the innovations are growing). And not because sales are falling or markets are shrinking (revenues are growing in general, and the markets are expanding with the expanding and ageing population). The key reason of the declining financial performance is the fact that research and development (R&D) costs are growing substantially faster over an average investment period, than the actual revenues over the same period. This kills operational profits, leading to a decline in the overall business gain. A direct consequence of that -- an increasingly stagnating industry, cutting sometimes promising R&D programs, jobs etc.
There are two more relevant questions here:
1) why R&D costs are growing faster than revenues, considering that technological progress is seemingly providing more and more optimal and powerful technologies to pharma companies at a constantly decreasing specific price (e.g. costs of computation, sequencing, screening and many other things are falling), and
2) what to do about it to reverse the decline in pharma industry performance?
(This post first appeared in Forbes)
Pioneered by expensive and cumbersome legacy electronic data interchange (EDI) systems, the B2B e-commerce market has been evolving, showing a staggering growth rate with a projected volume of $1.1 trillion in the U.S. alone and $6.7 trillion globally by 2020.
Interviews with experts
The application of artificial intelligence (AI) in the pharmaceutical industry has become a long-term strategic priority for most companies. However, the efficiency of this endeavor depends greatly on the availability of large volumes of properly curated quality data, which is not always the case.
While pharma organizations generate huge volumes of data across all stages of drug discovery, development, and commercialization, not all types of data are equally useful for building efficient machine learning (ML) pipelines. For instance, it is relatively easier to apply AI-tech to consumer-related business processes, where lots of well-understood and properly labeled data is available, than it is for basic research tasks, where data is complex, often poorly labeled and extremely domain-specific.
The above situation leads to a faster pace of progress with AI application in such areas as financial analysis, consumer-behavior prediction, patient classification, marketing, and so on.
One of the important hurdles that pharma companies are trying to solve using AI tech is brand management. Indeed, understanding peculiar features of various patient categories, their purchasing behaviors, reactions to different products, revealing possible risks and side-effects for each class -- those things become essential for pharma companies to be able to develop and implement truly patient-centric brand management strategies. Luckily, this is one of the most fruitful areas for the application of machine learning (especially deep learning) models.
To get a better understanding of how it can be done, I have asked several questions to Agnieszka Wolk, Senior Director, Data Science, IQVIA, who recently presented this topic at the PMSA 2019 European Summit in Basel, Switzerland. .
In this interview, Rasim Shah, Director at OKRA Technologies provided a glimpse into how the company applies state of the art machine learning technologies to solve real world challanges in the life sciences. Rasim also agreed to answer several questions about a more general context of AI in pharma, its current challanges and future perspective, as well as describe the current efforts the European Union puts into supporting the AI ecosystem in the region.
Rasim Shah, Director at OKRA Technologies:
OKRA Technologies is a leading European artificial intelligence (AI) company for life sciences. Our goal is to empower life science executives at their desks or whilst on the move, with explainable AI outputs. OKRA’s solutions deliver suggestions, predictions and explanations to enable life sciences executives and operational teams to drive the right drug to the right patient with humanised and understandable AI outputs. The OKRA engine learns from real-world data, structured, unstructured, clinical, commercial and scientific literature to drive the right insight to the different teams in life sciences. Our deep expertise in AI, combined with in-depth medical and product knowledge from life science leaders, has allowed us to develop and co-create products that can transform the way life sciences approach traditional industry challenges. We focus on operationalising AI in an ethical way by placing users of these systems at the centre.
Variational AI is a newly formed artificial intelligence (AI)-driven molecule discovery & drug design startup out of Vancouver, British Columbia, Canada. The company has developed Enki, an AI-powered small molecule discovery service.
The founders of Variational AI are planning to build on top of their state-of-the-art expertise in machine learning, reflected in more than 40 research publications, including those presented at NIPS/NeurIPS, ICML, ICLR, CVPR, ICCV, and other top events in the area of artificial intelligence research.
Editor's Pick: A Video Blog
The team at MIT created the most comprehensive database of metabolites, their interactions with proteins, protein-protein interactions, drug-protein interactions, and associations of metabolites with diseases. They then use the obtained interactions map to make inferences about the disease mechanisms and novel targets. With this new technology, the team launched a biotech startup ReviveMed in 2016 having raised $1.5M of funding so far.
“One-target-one-disease” paradigm has been around for decades, prompting numerous drug discovery programs focusing on identifying small molecules for targeting only one specific protein (or other targets) believed to be responsible for the disease mechanism.
Evaxion Biotech uses its machine learning-based platform to compare DNAs of tumor cells and DNAs healthy cells and identify mutations that are critical for the disease. This data is further used to design anticancer vaccines.
Artificial Intelligence Small Molecules Machine Learning In Silico Biopharma news Pharmaceutical industry trends Biotech Startup Big Data MedChem Database Thought-provoking Antibiotics R&D Outsourcing CROs Interviews Biologics